Insights
AIFA’s criteria for the implementation of monitoring registries
Introduction
The Italian Medicines Agency (AIFA) recently published comprehensive guidelines outlining the criteria for implementing monitoring systems through its registry platform. This initiative aims to improve transparency in decision-making processes and ensure the optimal use of healthcare resources. Here’s an overview of the key aspects of these guidelines.
Key Evaluation Criteria
The decision to establish a monitoring system involves a multifaceted assessment of the drug’s characteristics, therapeutic indications, and potential impact on healthcare expenditure. The main criteria include:
- Financial Impact
Medicines with a predicted expenditure of €80 million or more in their first three years (or €50 million for orphan drugs) may require monitoring. This ensures efficient allocation of resources while addressing uncertainties in cost predictions.
- Scientific and Technical Considerations
AIFA’s registries evaluate the appropriateness of drug usage based on robust clinical data, including trial results and regulatory dossiers. For complex treatments or those with uncertain efficacy and safety, monitoring is recommended to mitigate risks such as off-label use.
- Therapeutic Aggregation
A “therapeutic aggregation” occurs when two or more medicines, containing different active ingredients, have a monitoring registry (or other monitoring system) for the same therapeutic indication eligible for reimbursement.
Monitoring is prioritized for medicines sharing similar therapeutic indications or forming part of the same treatment algorithm. This ensures consistent oversight across comparable therapies.
- Advanced Therapies
Innovative treatments like gene or cell therapies are scrutinized, especially when they address non-rare conditions with high treatment costs.
- Patent Expiry
Monitoring through an AIFA registry is generally discouraged for medicines nearing patent expiration, but there are exceptions, e.g. drugs used for indications reimbursed according to law 648/96 or drugs included in multi-drug registries for specific regulatory purposes (e.g. drugs that are part of the pregnancy prevention program, PPP)
Types of Monitoring Systems
AIFA provides flexible monitoring tools tailored to the specific needs of each medicine:
- Comprehensive Registries
Capture detailed data across multiple parameters, including eligibility, treatment outcomes, and financial reimbursements.
- Simplified Registries
Focus on essential data collection, suitable for treatments with lower uncertainty or risks.
- Web-Based Therapeutic Plans
Streamlined tools for monitoring prescription appropriateness and treatment efficacy.
Managed Entry Agreements (MEAs)
AIFA’s platform supports MEAs to reduce financial uncertainties. These agreements, ranging from cost-sharing to outcome-based models, ensure that high-cost therapies are sustainable while maintaining financial accountability.
At RPN, we specialize in navigating complex pharmaceutical regulations, including monitoring frameworks like AIFA’s. Our integrated Regulatory & Market Access expertise and innovative compliance strategies ensures seamless integration of your products into the healthcare landscape. Let us support your success—connect with RPN to explore tailored solutions for your challenges.